Key facts
- This page summarizes Jonathan Finn's Form 4 filing for ATOSSA THERAPEUTICS, INC. (ATOS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 May 2025, 16:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025.